Entries |
Document | Title | Date |
20080249088 | Topical Delivery of Antifungal Drugs - A topical formula for treatment of antifungal infections of the skin and nails comprises: (a) a therapeutically effective amount of a benzylamine or morpholine antifungal compound; (b) an aliphatic alcohol substituted with an aromatic substituent in which the antifungal compound is soluble to a degree that a therapeutically effective concentration of the antifungal compound can be applied topically in solution; and (c) a distribution solvent or mixture of solvents in which the solvent mixture of parts (a) and (b) is soluble, and which has a boiling point that is less than about 110.degree.C. The benzylamine compound can be butenafine. The morpholine compound can be amorolfine. The aliphatic alcohol substituted with an aromatic substituent can be benzyl alcohol, or phenethyl alcohol. The distribution solvent mixture can include ethyl alcohol, water, or isopropyl alcohol. Alternatively, the formula can include a second antifungal compound. | 10-09-2008 |
20080261966 | BIS-ARYL SULFONAMIDES - Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists. | 10-23-2008 |
20090012074 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor - The present invention relates to aromatic compounds of the formula I | 01-08-2009 |
20090048243 | THERAPEUTIC AGENT FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER - A prophylactic and/or therapeutic drug for AD/HD, containing teniloxazine or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, as the active ingredient. | 02-19-2009 |
20090054426 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity. | 02-26-2009 |
20090062271 | Antithrombotic Diamides - This application relates to a compound of formula I (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. | 03-05-2009 |
20090075993 | Pharmaceutically effective compounds - The subject invention relates to carboxamidine derivatives, to pharmaceutical compositions comprising the same, and the use thereof in the preparation of pharmaceutical compositions for the treatment of vascular diseases. | 03-19-2009 |
20090075994 | DEUTERIUM-ENRICHED RADAFAXINE - The present application describes deuterium-enriched radafaxine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090105237 | Cooling compounds - A method of conferring a cooling effect on the skin or mucous membranes by applying thereto at least one compound of the Formula I: | 04-23-2009 |
20090105238 | Compounds and Relative use for the Control of Phytopathogens - Amphoteric compounds are described, having a zwitterionic structure of the betainic type having general formula (I) | 04-23-2009 |
20090118267 | INDANES - Compounds of the formula (I), in which R | 05-07-2009 |
20090118268 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS - This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy. | 05-07-2009 |
20090156591 | Thiophene and Thiazole Substituted trifluoroethanone Derivatives as Histone Deacetylase (Hdac) Inhibitors - The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or stereoisomer thereof. The compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases. | 06-18-2009 |
20090170841 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders - The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease. | 07-02-2009 |
20090170842 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE - A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof, and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1. | 07-02-2009 |
20090215764 | Antimicrobial agents - Provided herein are substituted aromatic compounds, which are tRNA synthetase inhibitors, and hence can be used as antimicrobial agents. Compounds described herein can be used for the treatment or prevention of a condition caused by or contributed to by gram positive, gram negative, anaerobic bacteria or fungal organisms, more particularly against bacterium, for example, | 08-27-2009 |
20090270384 | MORPHOLINE DOPAMINE AGONISTS - The present invention provides for compounds of formula (I), (Ia) and (Ib) | 10-29-2009 |
20090286775 | Bicyclic Derivatives as P38 Kinase Inhibitors - New bicyclic derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors. | 11-19-2009 |
20090286776 | HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF - Compounds of the formula (I): in which R, R | 11-19-2009 |
20090312315 | PAI-1 INHIBITOR - The compound represented by the following formula (I) and the like have PAI-1 inhibition activity; | 12-17-2009 |
20090318433 | VERY FAST TIME RESOLVED IMAGING IN MULTIPARAMETER MEASUREMENT SPACE - The present invention provides new method of treatment of Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamine derivatives that constitute antagonists of the H | 12-24-2009 |
20100022526 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES - The present invention relates to compounds of formula (I) wherein R | 01-28-2010 |
20100035873 | Diaryl Compounds and Uses Thereof - The invention relates to derivatives of a compound of formula I: | 02-11-2010 |
20100041648 | METHODS FOR TREATING RETROVIRAL INFECTIONS - The present invention provides compositions for treating an HIV infection comprising administering a compound according to formula I where Ar, R | 02-18-2010 |
20100048549 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 - The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein A, D, E, J, Q1 R1, R2, R3, p and j are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes sst | 02-25-2010 |
20100048550 | SELECTIVE TR-BETA 1 AGONIST - The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta(TR-Beta). Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them. | 02-25-2010 |
20100063044 | SUBSTITUTED ANILINE DERIVATIVES - The present invention relates to aniline derivatives of formula I: | 03-11-2010 |
20100105671 | C7-fluoro substituted tetracycline compounds - The present invention is directed to a compound represented by Structural Formula (A): | 04-29-2010 |
20100113438 | CLASS OF HISTONE DEACETYLASE INHIBITORS - New histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH | 05-06-2010 |
20100152179 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity. | 06-17-2010 |
20100173904 | Topical composition, topical composition precursor, and methods for manufacturing and using - A tropical composition is provided. The topical composition can be prepared by diluting a topical composition precursor with water and adding additional components, if desired. The topical composition precursor can be prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups wherein the alkylene groups contain at least 10 carbon atoms, and a hydrophilic polymer composition including repeating carboxylic groups and/or repeating hydroxyl groups. A topical composition precursor and methods for manufacturing and using a topical composition are provided by the invention. | 07-08-2010 |
20100184757 | FUNGICIDALLY ACTIVE COMPOUND COMBINATIONS - Active compound mixtures comprising ipconazole and at least one further fungicidally active compound are highly suitable for protecting industrial materials against colonization and destruction by microorganisms. | 07-22-2010 |
20100222337 | FUNGICIDAL COMPOSITION CONTAINING CARBOXYLIC ACID AMIDE DERIVATIVE - Conventional fungicidal compositions have had practical problems such that either a preventive effect or a curative effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends to be inadequate depending upon the application site, and a fungicidal composition to overcome such problems has been desired. The present invention provides a fungicidal composition containing a carboxylic acid amide derivative of the formula (I) or a salt thereof, as an active ingredient: wherein A is phenyl which may be substituted, benzodioxolanyl which may be substituted, or benzodioxanyl which may be substituted; B is 2- or 3-pyridyl which may be substituted; each of R | 09-02-2010 |
20100249125 | INHIBITION OF PROSTGLANDIN E2 RECEPTORS FOR THE TREATMENT OF ENDOMETRIOSIS - The present invention describes the selective inhibition of prostaglandin receptors (PGE | 09-30-2010 |
20100286138 | Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide - Polymorphic forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide are provided together with a process for the manufacture of said compound. | 11-11-2010 |
20110046128 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS - A series of novel compounds showing anticonvulsant, chemical countermeasure(s), and analgesic activities is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), chronic neurodegenerative diseases (such as Alzheimer's disease and Huntington's disease), and/or traumatic brain and/or spinal cord injuries. Moreover, these/such compounds may also be useful in the treatment of status epilepticus and/or as chemical countermeasures. | 02-24-2011 |
20110118254 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE - The main object of the present invention is to provide an agent for the treatment of inflammatory bowel diseases. | 05-19-2011 |
20110160200 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension - The invention relates to methods of treating, preventing or delaying the onset or development of pulmonary hypertension using hydroxyl donors or pharmaceutically acceptable salts thereof. The invention further relates to methods of reducing mean pulmonary arterial pressure using hydroxyl donors or pharmaceutically acceptable salts thereof. | 06-30-2011 |
20110190285 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT - The present invention provides methods of treating a botulinum toxin related condition in a subject. In certain embodiments, the methods involve administering a compound of the following formulas: (I), (II), (III), (IV), (V). | 08-04-2011 |
20120165325 | Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide - Polymorphic forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide are provided together with a process for the manufacture of said compound. | 06-28-2012 |
20120309753 | METHOD OF DISSOLVING ANTIFUNGAL AGENT, AND COMPOSITIONS WITH A HIGH CONCENTRATION OF ANTIFUNGAL AGENT, SUITABLE FOR APPLICATION TO THE NAIL - A pharmaceutical composition is described which includes: an antifungal agent from the class of the allylamines or the morpholines, at a concentration of at least 5%; a ternary solvent system comprising water; at least one branched or straight chain C2-C8 alkanol; at least one glycol; the total amount of water representing more than 30% (w/w) of the composition. This composition is intended for application to the nail for the treatment of onychomycoses. | 12-06-2012 |
20120322796 | BENZOCYCLOHEPTANE AND BENZOXEPINE DERIVATIVES - The present invention relates to a compound of formula (I) | 12-20-2012 |
20130150357 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE - The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity. | 06-13-2013 |
20130203752 | PHENYLMORPHOLINES AND ANALOGUES THEREOF - Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceutical compositions comprising one or more of these compounds or prodrugs, which may further comprise one or more additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to modification of monoamine neutrotransmitter levels, such as pre-obesity, obesity, addiction, and depression. | 08-08-2013 |
20140051693 | TREATMENT FOR CEREBRAL PALSY IMPAIRED SPEECH IN CHILDREN - Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment. | 02-20-2014 |
20140113895 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC - A compound or its pharmaceutically acceptable salt, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within. | 04-24-2014 |
20140163024 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS - Compounds of the formula Ia or Ib: | 06-12-2014 |
20140194415 | FATTY ACID SYNTHASE INHIBITORS - This invention relates to spirocyclic piperidines according to Formula (I) and the use of spirocyclic piperidines for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of spirocyclic piperidines in the treatment of cancer. | 07-10-2014 |
20140329811 | Methods of Modulating Cell Proliferation and Cyst Formation in Polycystic Kidney and Liver Diseases - The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease. | 11-06-2014 |
20150087642 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS - Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions. | 03-26-2015 |
20160022610 | COMBINATION TREATMENT COMPRISING BUPROPION ( (.+-.)-2-(TERT-BUTYLAMINO)-1-(3-CHLOROPHENYL)PROPAN-1-ONE) AND A SYMPATHOMIMETIC DRUG FOR WEIGHT CONTROL AND TREATING OBESITY - Compositions and methods for controlling weight gain and treating obesity are disclosed. Compositions include bupropion and a sympathomimetic drug. Methods for controlling weight include administering a composition including a combination of bupropion and a sympathomimetic drug. Methods for treating obesity include administering a composition including a combination of bupropion and a sympathomimetic drug. The active agents of the composition may be administered at a lower dosages than either drug separately with less side effect risk and allow for longer periods of administration to increase the time for controlling weight loss and treating obesity. | 01-28-2016 |
20160137592 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS - A series of novel amides showing broad pharmaceutical activity. Compounds described herein are effective as anticonvulsants, chemical countermeasures, and analgesics. Such compounds also show, neuroprotective/neuroreparative effects and activity against spinal muscular atrophy. Such pharmaceutically active compounds show utility in the treatment of central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's, ALS, and Huntington's disease) spasticity, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), and/or traumatic brain and/or spinal cord injuries. | 05-19-2016 |
20160200674 | IDO INHIBITORS | 07-14-2016 |